Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types
Jammbe Musoro(Amsterdam UMC Location University of Amsterdam), Andrew Bottomley(European Organisation for Research and Treatment of Cancer), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam), Katarzyna Pogoda(Unknown), Susanne Singer(Rostock University of Music and Theatre), Yvonne Brandberg(Karolinska Institutet), Linda Dirven(Leiden University Medical Center), Samantha C. Sodergren(University of Southampton), Corneel Coens(European Organisation for Research and Treatment of Cancer), Galina Velikova(University of Leeds), Alexander M.M. Eggermont(University Medical Center Utrecht), Elfriede Greimel(Medical University of Graz), Martin Taphoorn(Leiden University Medical Center), Hans‐Henning Flechtner(Jagiellonian University), Michael Koller(University Hospital Regensburg), Eva‐Maria Gamper(Innsbruck Medical University), Mirjam A. G. Sprangers(GGD Amsterdam), Madeleine King(The University of Sydney), Mogens Grøenvold(University of Copenhagen), Kim Cocks(University of Leeds)
Cited by 189
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
EORTC QLQ-C30 Scoring Manual
|Research at the University of Copenhagen (University of Copenhagen)|1995|2.4k
Translation, Validation, and Norming of the Dutch Language Version of the SF-36 Health Survey in Community and Chronic Disease Populations
|Journal of Clinical Epidemiology|1998|2.3k